On Invalid Date, Viking Therapeutics (NASDAQ: VKTX) reported Q4 2023 earnings per share (EPS) of -$0.25, up 3.85% year over year. Total Viking Therapeutics earnings for the quarter were -$24.61 million. In the same quarter last year, Viking Therapeutics's earnings per share (EPS) was -$0.26.
As of Q1 2024, Viking Therapeutics's earnings has grown year over year. Viking Therapeutics's earnings in the past year totalled -$85.90 million.
What is VKTX's earnings date?
Viking Therapeutics's earnings date is Invalid Date. Add VKTX to your watchlist to be reminded of VKTX's next earnings announcement.
What was VKTX's revenue last quarter?
On Invalid Date, Viking Therapeutics (NASDAQ: VKTX) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Viking Therapeutics's revenue was $0.00.
What was VKTX's revenue growth in the past year?
As of Q1 2024, Viking Therapeutics's revenue has grown null year over year. Viking Therapeutics's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.